Australia's most trusted source of pharma news
Friday, 20 April 2018
Lost Your Access?
Aust leads in patent expiries
List of highly anticipated US LOEs shows Aust ahead of the curve.
BMS, AZ report local results
Aust revenue fairly steady but increased costs drag on profits.
TGA's new $6m+ fine plan
Failure to report drug shoratges could prove very expensive.
P&G buys Merck consumer
Pays 3.4 billion euros for expanded footprint.
Cancer patients' hopes high
Breast cancer lobby bullish on positive PBAC outcome.
GSK, MSD target market share
Head-to-head trials in COPD, pneumococcal.
Shire sells oncology to Servier
Surprise sale may stymie Takeda bid.
Roche taps Aussie to lead NZ
Current business unit director to take up new role in July.
Hodgkins at last for Keytruda
MSD's optimism rewarded as health minister reveals three key additions to the PBS.
ACCC v GSK, Novartis heats up
Misleading claims action over Voltaren Osteo Gel heads for trial.
Four new drugs nigh
Cancer, hep and CF therapies fast approach local market.
Orkambi tries PBAC again
Will it be fourth time lucky for the hapless CF contender?
Cancer market waits results
PBAC about to reveal whether new therapies can move.
Aust CAR-T gains funding
Latest MTPConnect grants look to cancer's cutting edge.
Aust hit by global EpiPen drought
Mylan scrambles as UK, Canada and Aust struggle with low supply.
Hunt strokes pharmacy sector
Minister tells pharmacists 'very confident' 7CPA will be generous.
BMS combo scores kidney win
Opdivo+Yervoy granted first-line use after fast review.
Mylan takes seat with grown-ups
This formerly shy wallflower is flexing new muscles.
Copies build for Janssen's $60m drug
Competitors line up anticpating blood cancer therapy expiry.
Events & Conferences
© 2003 - 2018 Lush Media
Pharma in Focus
Jolly Good Design